Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538753 | 0.82 | ACHE (0.44) | ADRA1DADRA1AADRA1BACHE | |
| SCHEMBL10417787 | 0.79 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL30064399 | 0.78 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BACHESIGMAR1 | |
| SCHEMBL9592796 | 0.78 | SIGMAR1 (0.54) | SIGMAR1 | |
| SCHEMBL124097 | 0.77 | SIGMAR1 (0.59) | SIGMAR1 | |
| SCHEMBL21315846 | 0.77 | SIGMAR1 (0.59) | SIGMAR1 | |
| SCHEMBL18917470 | 0.77 | ACHE (0.47) | ADRA1DADRA1AADRA1BACHE | |
| SCHEMBL2063016 | 0.77 | GPR119 (0.43) | ACHE | |
| SCHEMBL3490370 | 0.77 | GPR119 (0.43) | ACHE | |
| SCHEMBL7240012 | 0.76 | SIGMAR1 (0.58) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | ADRA1D 1667/4885ADRA1A 1727/4885ADRA1B 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.